Rapport Therapeutics, Inc. - Officer Stock Sale

Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics, Inc., sold 20,225 shares of common stock on April 17, 2026. The sale was executed as part of a Rule 10b5-1 trading plan adopted on December 10, 2025. The shares were sold at a weighted average price of $39.9923, with individual transactions ranging from $39.90 to $40.38. Following this transaction, Krishnaswamy owns 246,426 shares of the company's stock. Full details regarding the specific prices of each transaction will be provided upon request to the SEC, the Issuer, or any security holder.